152 related articles for article (PubMed ID: 17431617)
1. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome.
Wang H; Song S; Kou G; Li B; Zhang D; Hou S; Qian W; Dai J; Tian L; Zhao J; Guo Y
Cancer Immunol Immunother; 2007 Nov; 56(11):1775-83. PubMed ID: 17431617
[TBL] [Abstract][Full Text] [Related]
2. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice.
Smallshaw JE; Ghetie V; Rizo J; Fulmer JR; Trahan LL; Ghetie MA; Vitetta ES
Nat Biotechnol; 2003 Apr; 21(4):387-91. PubMed ID: 12627168
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab') fragments.
Gao J; Kou G; Chen H; Wang H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Mol Cancer Ther; 2008 Oct; 7(10):3399-407. PubMed ID: 18852143
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
5. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
7. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
[TBL] [Abstract][Full Text] [Related]
8. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
11. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
12. Construction and expression of novel immunotoxin cpIL-4(13D)-PE38KDEL with increased activity.
Cui JX; Ji JF; Lv AG; Wu WF
Biochemistry (Mosc); 2005 Jan; 70(1):62-8. PubMed ID: 15701050
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Liu XY; Pop LM; Schindler J; Vitetta ES
MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
[TBL] [Abstract][Full Text] [Related]
15. [Construction, expression and targeting therapeutic of single-chain immunotoxin against hepatocellular carcinoma].
Zhang J; Liu YF; Yang SJ; Qiao Q; Cheng H; Ma FC; Chen WL
Zhonghua Gan Zang Bing Za Zhi; 2004 Mar; 12(3):148-50. PubMed ID: 15059298
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of a high-affinity humanized SM5-1 monoclonal antibody.
Li B; Wang H; Zhang D; Qian W; Hou S; Shi S; Zhao L; Kou G; Cao Z; Dai J; Guo Y
Biochem Biophys Res Commun; 2007 Jun; 357(4):951-6. PubMed ID: 17451647
[TBL] [Abstract][Full Text] [Related]
18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
19. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Hu J; Dong A; Fernandez-Ruiz V; Shan J; Kawa M; MartÃnez-Ansó E; Prieto J; Qian C
Cancer Res; 2009 Sep; 69(17):6951-9. PubMed ID: 19690140
[TBL] [Abstract][Full Text] [Related]
20. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.
Kondapaneni M; McGregor JR; Salvemini D; Laubach VE; Samlowski WE
J Immunother; 2008 May; 31(4):325-33. PubMed ID: 18391763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
